GlassScriptPhysician profile
Mohammad Daud Nawabi
NPI 1275554594
$3,005.42
in general payments reported to CMS, 2019-2025
44 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.09 · 2020: $44.39 · 2021: $886 · 2022: $1,554 · 2023: $261 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.94 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $332.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $189.49 | 2020-2022 | |
| Incyte Corporation | $183.99 | 2021-2025 | Zynyz, Monjuvi, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $150.34 | 2020-2023 | Opdivo |
| Genzyme Corporation | $137.26 | 2021-2022 | |
| Seagen INC. | $135.94 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $135.00 | 2021-2023 | Keytruda |
| Celgene Corporation | $129.81 | 2021-2023 | Pomalyst |
| Genentech USA, INC. | $129.50 | 2022-2025 | Venclexta, Phesgo, Perjeta |
| Amgen INC. | $128.66 | 2021-2022 | |
| Glaxosmithkline, LLC. | $104.78 | 2021-2023 | Jemperli, Zejula |
| Gilead Sciences, INC. | $100.69 | 2021-2025 | Trodelvy |
| Taiho Oncology, INC. | $93.81 | 2022 | |
| Jazz Pharmaceuticals INC. | $78.80 | 2020-2025 | |
| Pfizer INC. | $76.45 | 2022-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Nawabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.